Markets:

Overview

News

Currencies

International

Treasuries

Eli Lilly (NY:LLY)

1,015.54 -7.68 (-0.75%)

Streaming Delayed Price Updated: 9:59 AM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Eli Lilly Breaks New Ground In Crohn's Disease Treatment ↗

Today 7:23 EST

Eli Lilly (LLY) reports landmark Phase 3 data for Omvoh, showing over 90% of Crohn's disease patients achieved 3-year steroid-free remission.

Via Benzinga

Is Pfizer Stock the Only Big Pharma Name I'd Buy and Hold Through Any Market Crash? ↗

Today 3:05 EST

New products are already generating growth.

Via The Motley Fool

Topics Intellectual Property

ORBIMED Advisors Trims $125 Million Terns Stake After a Breakout Year, According to SEC Filing ↗

Today 0:22 EST

Terns Pharmaceuticals has delivered a significant rally over the past year, lifting expectations around its clinical pipeline. The latest filing shifts attention to upcoming data and the company’s...

Via The Motley Fool

Topics Regulatory Compliance

Eli Lilly & Co (NYSE:LLY) Combines Explosive Growth with a Bullish Technical Setup ↗

February 17, 2026

Via Chartmill

3 Market-Beating Stocks to Consider Right Now

February 19, 2026

Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three for years on end are almost always the...

Via StockStory

2 Innovative Biotech Stocks That May Climb 58% and 200%, According to Wall Street ↗

February 19, 2026

These biotech companies have catalysts ahead.

Via The Motley Fool

Warning: This Skyrocketing Stock Has a Hidden Risk ↗

February 19, 2026

Eli Lilly is leading the pack in the GLP-1 weight-loss drug market, but this good news won't last forever.

Via The Motley Fool

Topics Intellectual Property

Prediction: Eli Lilly Stock Could Surge 45% This Year ↗

February 19, 2026

Eli Lilly just delivered explosive growth, and analysts see up to 45% upside, but is this pharma giant still a buy at its current price?

Via The Motley Fool

Overlooked and Undervalued: Why Novo Nordisk Stock Deserves Attention ↗

February 19, 2026

Novo Nordisk looks attractively priced even though 2026 is likely to be a tough year.

Via The Motley Fool

Is Viking Therapeutics Stock Really Going to $125? ↗

February 19, 2026

Never say never. There's certainly a mathematical path to that level, if the company navigates it correctly.

Via The Motley Fool

3 Stocks to Buy and Hold for 2026 and Beyond ↗

February 19, 2026

Any of these three pharmaceutical titans could move the needle in your portfolio.

Via The Motley Fool

Topics Economy Intellectual Property

Pfizer’s BRAFTOVI BREAKWATER Trial Delivers Landmark Survival Gains in Colorectal Cancer

February 19, 2026

NEW YORK — Pfizer Inc. (NYSE: PFE) has announced breakthrough results from its Phase 3 BREAKWATER clinical trial, demonstrating that its BRAFTOVI (encorafenib) regimen significantly improves both...

Via MarketMinute

Forget Ozempic: This Obesity‑Drug Giant Is Grabbing the Biggest Slice of the GLP‑1 Gold Rush ↗

February 19, 2026

Ozempic's rival is generating blockbuster revenue and gaining market share.

Via The Motley Fool

Nasdaq, S&P 500 Futures Edge Higher, Trump Speech In Focus: Why WMT, META, IBRX, MSFT, EBAY Are On Traders' Radar Today ↗

February 19, 2026

Data from Stocktwits indicated retail sentiment towards SPY and QQQ cooled to neutral.

Via Stocktwits

Topics ETFs Economy Government

2 High-Flying Stocks on Our Buy List and 1 Facing Challenges

February 18, 2026

Expensive stocks typically earn their valuations through superior growth rates that other companies simply can’t match. The flip side though is that these lofty expectations make them particularly...

Via StockStory

Topics Firearms

Here's How Much You Would Have Made Owning Eli Lilly Stock In The Last 15 Years ↗

February 18, 2026

Via Benzinga

Eli Lilly's Landmark Trial Shows Major Psoriasis-Obesity Breakthrough With Taltz-Zepbound Combo ↗

February 18, 2026

Eli Lilly's latest trial results and new licensing agreement show promise in treating psoriasis, obesity, and kidney disease.

Via Benzinga

Health Care Sector (XLV) Shows Resilience Amid Tech Volatility and Strong Jobs Data

February 18, 2026

As the broader market grappled with a violent valuation reset in the technology sector, the health care industry emerged as a critical anchor for investors in early 2026. The Health Care Select Sector...

Via MarketMinute

Topics Artificial Intelligence ETFs Earnings

The Trillion-Dollar Pharmaceutical Giant: Eli Lilly Makes History as Weight-Loss Revolution Drives Unprecedented Growth

February 17, 2026

In a historic moment for the global healthcare industry, Eli Lilly and Company (NYSE:LLY) has officially cemented its position as the world’s first pharmaceutical company to surpass a $1 trillion...

Via MarketMinute

Topics Earnings Economy

Should You Buy the Vanguard S&P 500 ETF With the Stock Market Near a Record High? History Offers a Clear Answer ↗

February 17, 2026

Despite recent volatility, trends like artificial intelligence could fuel another strong year for the stock market.

Via The Motley Fool

Topics Artificial Intelligence ETFs Stocks

Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash ↗

February 17, 2026

Agios Pharmaceuticals targets rare blood disorders with a marketed anemia drug and a focused clinical-stage pipeline.

Via The Motley Fool

Topics Regulatory Compliance

Cogent Biosciences Stock Soars 346% in a Year, but One Fund Just Sold Off $4.5 Million ↗

February 17, 2026

This biotech firm develops precision therapies targeting rare genetic diseases, with a lead candidate focused on oncology indications.

Via The Motley Fool

Topics Regulatory Compliance

Structure Therapeutics Stock Up 187% in One Year as Fund Trims $8 Million From Stake ↗

February 17, 2026

Structure Therapeutics develops oral therapies for chronic diseases, using a proprietary platform to target G-protein-coupled receptors.

Via The Motley Fool

Kymera Therapeutics Stock Up 120% in 1 Year as Fund Adds $3 Million More ↗

February 17, 2026

Kymera Therapeutics develops targeted protein degradation therapies for immunology and oncology, advancing multiple clinical-stage programs.

Via The Motley Fool

1 Reason I'd Buy Eli Lilly Stock and Never Sell ↗

February 17, 2026

A robust pipeline is essential for a buy-and-hold pharmaceutical stock.

Via The Motley Fool

Topics Intellectual Property

The Biotechnology Renaissance: AI and Capital Collide in a Multi-Trillion Dollar Pivot

February 17, 2026

As of February 17, 2026, the biotechnology sector is undergoing its most significant structural transformation in decades, a period now widely termed the "Biotechnology Renaissance." Following a...

Via MarketMinute

Topics Artificial Intelligence Economy Initial Public Offering

NVO Stock Generates Retail Buzz After European Commission Approves 7.2 MG Once-Weekly Dose Of Wegovy Injection ↗

February 17, 2026

The approval follows a positive recommendation from the European Medicines Agency and is supported by data from clinical trials involving more than 1,400 participants.

Via Stocktwits

Topics Lawsuit

Hims & Hers Faces New Hurdle In Weight-Loss Brawl With Novo Nordisk ↗

February 17, 2026

Novo Nordisk and the FDA are both mounting pressure on Hims & Hers Health and other GLP-1 compounders.

Via Investor's Business Daily

Topics Lawsuit

2026 Could Be a Big Year for Viking Therapeutics. Time to Buy? ↗

February 17, 2026

Viking should have plenty of news to share with investors this year.

Via The Motley Fool

Eli Lilly's Experimental Cancer Drug Cuts Recurrence Risk In Early-Stage Lung Cancer Patients ↗

February 17, 2026

Eli Lilly's lung cancer trial shows lower recurrence risk and strong survival benefit in early-stage patients.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Eli Lilly (NY:LLY)

Headline News about Eli Lilly

Starting at $3.75/week.

Subscribe Today